Pro Bono Bio has reported that its new nanotechnology-based product for treatment of osteoarthritis called FLEXISEQ has been approved to be sold in Malaysia. This comes on the heels of the successful debut of FLEXISEQ in the European market earlier this year.
Pro Bono Bio has also inked a distribution deal with Farmasia to sell FLEXISEQ in the Malaysian market. Farmasia will start selling the product from early July 2012. FLEXISEQ was introduced to the local market during the 42nd Annual Scientific Meeting of the Malaysian Orthopaedic Association held in Kuantan, Malaysia from June 14 to 17, 2012.
According to Pro Bono Bio’s Chief Operating Officer, Michael Earl, Pro Bono Bio is a committed international pharmaceutical company which looks forward to provide a better experience to patients, payers and doctors by designing advanced products to handle areas of concern. The company is happy to debut FLEXISEQ in Malaysia after a successful launch in Europe. The company expects to launch more advanced products in 2012 and is also in discussion to select site for regional headquarters and production facilities to support its products in South East Asia.
Farmasia’s Zohrah Razak Al Aidruss stated that the company is happy to ink a distribution deal to launch such an advanced product in the Malaysian market. The distinctive mode of action and no side effects make FLEXISEQ a sought after product for physicians handling osteoarthritis. Millions of patients are affected by osteoarthritis in Malaysia, and both local and worldwide trials have corroborated the efficacy of FLEXISEQ in mitigating joint pain, a symptom of osteoarthritis.
Source: http://www.probonobio.com
Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.